Oncolytics Biotech, Inc. (ONCY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 71/100 (HIGH), 1.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.64% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 4 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 16, 2026 · ingested Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 17, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 17, 2026 |
| Publications | 52 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 16, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 56.5/100 (grade C):
- Clinical trials: signal score 0.54, weight used 68%, 37.1 points
- Dilution risk: signal score 0.71, weight used 22%, 15.6 points
- Short interest: signal score 0.30, weight used 8%, 2.5 points
- Publications: signal score 1.00, weight used 1%, 1.4 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor
- Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
- Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
- Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
- Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
- Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
- Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma. — Proc Natl Acad Sci U S A 2026 Oct 6 PMID 42804630
- Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now? — Ther Innov Regul Sci 2026 Sep PMID 42380698
- Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma. — Int J Cancer 2026 Jun 15 PMID 41696944
- A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study. — Clin Cancer Res 2025 Jul 1 PMID 40300087
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects. — J Hematol Oncol 2025 Jan 20 PMID 39828738
52 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Oncolytics Biotech, Inc..
Full ONCY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.